Latest / Parkinson's Disease Education Podcast

Prasinezumab Moves to Phase III — What That Means for Parkinson's Patients
Roche/Genentech announced on June 15–16, 2025 that prasinezumab — an anti-α-synuclein monoclonal antibody — will enter Phase III trials for early Parkinson's disease after mixed but encouraging Phase II signals.
In this episode (watch on YouTube) we explain the biology behind α-synuclein targeting, summarize the PASADENA and PADOVA findings (what was missed and what looked promising), discuss safety issues and trial design challenges, and speak with experts/patients about realistic timelines and hopes for disease-modifying therapies
To follow trials like this and to have customized…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.